|
Gap Junctions
|
A11.284.149.165.420.471 |
|
|
Intercellular Junctions
|
A11.284.149.165.420 |
|
|
Sclerosing Solutions
|
D27.505.954.411.700 |
|
|
Kingella kingae
|
B03.660.075.525.410.410 |
|
|
Withanolides
|
D04.210.500.247.222.537.888 |
|
|
Ergosterol
|
D04.210.500.247.222.537 |
|
|
Communicable Diseases, Emerging
|
D021821 |
[Infectious diseases that are novel in their outbreak ranges (geographic and host) or transmission mode.
] |
|
Cyclic GMP-Dependent Protein Kinase Type II
|
D12.776.476.200.150.750 |
|
|
Cyclic GMP-Dependent Protein Kinases
|
D12.776.476.200.150 |
|
|
Dental Clinics
|
N02.278.192.250 |
|
|
Ubiquitin-Specific Proteases
|
D08.811.277.656.300.887 |
|
|
Fluprednisolone
|
D04.210.500.745.432.769.795.307 |
|
|
Prednisolone
|
D04.210.500.745.432.769.795 |
|
|
Aquaporin 1
|
D12.776.543.585.400.730.040.436 |
|
|
Systems Integration
|
L01.906.787 |
|
|
Sulfadoxine
|
D02.065.884.725.765 |
|
|
GATA4 Transcription Factor
|
D12.776.260.257.400 |
|
|
GATA Transcription Factors
|
D12.776.260.257 |
|
|
Hemoglobin C Disease
|
C16.320.365.463 |
|
|
Hemoglobinopathies
|
C16.320.365 |
|
